Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy.
Mouli ChakrabortyChantal SellierMichel NeyVilla PascalNicolas Charlet-BerguerandRubén ArteroBeatriz LlamusiPublished in: Disease models & mechanisms (2018)
Myotonic dystrophy (DM) is a dominantly inherited neuromuscular disorder caused by expression of mutant myotonin-protein kinase (DMPK) transcripts containing expanded CUG repeats. Pathogenic DMPK RNA sequesters the muscleblind-like (MBNL) proteins, causing alterations in metabolism of various RNAs. Cardiac dysfunction represents the second most common cause of death in DM type 1 (DM1) patients. However, the contribution of MBNL sequestration in DM1 cardiac dysfunction is unclear. We overexpressed Muscleblind (Mbl), the DrosophilaMBNL orthologue, in cardiomyocytes of DM1 model flies and observed a rescue of heart dysfunctions, which are characteristic of these model flies and resemble cardiac defects observed in patients. We also identified a drug - daunorubicin hydrochloride - that directly binds to CUG repeats and alleviates Mbl sequestration in Drosophila DM1 cardiomyocytes, resulting in mis-splicing rescue and cardiac function recovery. These results demonstrate the relevance of Mbl sequestration caused by expanded-CUG-repeat RNA in cardiac dysfunctions in DM1, and highlight the potential of strategies aimed at inhibiting this protein-RNA interaction to recover normal cardiac function.
Keyphrases
- end stage renal disease
- left ventricular
- chronic kidney disease
- newly diagnosed
- glycemic control
- ejection fraction
- heart failure
- prognostic factors
- peritoneal dialysis
- poor prognosis
- oxidative stress
- type diabetes
- insulin resistance
- patient reported outcomes
- metabolic syndrome
- endothelial cells
- atrial fibrillation
- weight loss
- long non coding rna